Commonwealth Equity Services’s Myriad Genetics MYGN Stock Holding History

Commonwealth Equity Services’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-5,495	Closed	-$205K	–	2836
2018 Q2	$205K	Buy	+5,495	New	+$186K	﹤0.01%	2446
2018 Q1	–	Sell	-6,203	Closed	-$213K	–	2765
2017 Q4	$213K	Buy	6,203 +593	+11%	+$20K	﹤0.01%	2318
2017 Q3	$203K	Buy	+5,610	New	+$160K	﹤0.01%	2274
2016 Q1	–	Sell	-5,143	Closed	-$222K	–	2244
2015 Q4	$222K	Buy	+5,143	New	+$217K	﹤0.01%	1809
2015 Q3	–	Sell	-7,145	Closed	-$243K	–	2196
2015 Q2	$243K	Sell	7,145 -1,095	-13%	-$37.2K	﹤0.01%	1786
2015 Q1	$292K	Buy	8,240 +1,036	+14%	+$37.1K	﹤0.01%	1657
2014 Q4	$245K	Sell	7,204 -728	-9%	-$25.8K	﹤0.01%	1704
2014 Q3	$306K	Sell	7,932 -1,131	-12%	-$42.2K	﹤0.01%	1540
2014 Q2	$353K	Buy	+9,063	New	+$337K	﹤0.01%	1436

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Commonwealth Equity Services's MYGN Position: Q3 2018 in Review

Commonwealth Equity Services sold out of Myriad Genetics (MYGN) in Q3 2018, closing a stake of 5,495 shares — an estimated $205K sold.

Commonwealth Equity Services first reported a position in MYGN in Q2 2014 and held it in 9 quarters. The position peaked at $353K in Q2 2014. 284 funds tracked by Wall St. Rank hold MYGN as of Q3 2018.

Commonwealth Equity Services reported no remaining Myriad Genetics position as of Q3 2018 after selling out during the quarter.
Commonwealth Equity Services sold 5,495 Myriad Genetics shares in Q3 2018, an estimated $205K.
Commonwealth Equity Services first reported a position in Myriad Genetics in Q2 2014 and held it in 9 quarters.
Commonwealth Equity Services's Myriad Genetics position peaked at $353K in Q2 2014.
284 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2018.

Based on Commonwealth Equity Services's 13F filing for Q3 2018, filed 6 Nov 2018.